Summarized by Masters of Longevity from Longevity Technology.
A partnership-focused article describing a multimodal approach that pairs blood-based biomarkers with AI-driven digital cognitive measures to improve early Alzheimer’s detection and trial workflows.
Key Takeaways
- Combining blood circRNA biomarkers with AI-based digital cognitive measures can enable earlier identification of individuals at risk for Alzheimer’s disease.
- A multimodal workflow pairing digital screening with confirmatory blood testing may improve patient stratification and longitudinal monitoring in trials and clinical care.
- Integrating digital neuromarkers and blood signatures could reduce reliance on specialist assessments and help scale routine Alzheimer’s diagnostic pathways.
